List of Excipients in API OLAPARIB
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing OLAPARIB
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | LYNPARZA | olaparib | 0310-0668 | COPOVIDONE K25-31 | 2027-09-08 |
| AstraZeneca Pharmaceuticals LP | LYNPARZA | olaparib | 0310-0668 | FERRIC OXIDE YELLOW | 2027-09-08 |
| AstraZeneca Pharmaceuticals LP | LYNPARZA | olaparib | 0310-0668 | FERROSOFERRIC OXIDE | 2027-09-08 |
| AstraZeneca Pharmaceuticals LP | LYNPARZA | olaparib | 0310-0668 | HYPROMELLOSE | 2027-09-08 |
| AstraZeneca Pharmaceuticals LP | LYNPARZA | olaparib | 0310-0668 | MANNITOL | 2027-09-08 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for OLAPARIB
Excipient focus: COPOVIDONE K25-31
OLAPARIB drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
OLAPARIB drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
OLAPARIB drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
OLAPARIB drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
OLAPARIB drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
OLAPARIB drug variants containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
OLAPARIB drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
OLAPARIB drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
OLAPARIB drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
OLAPARIB drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | olaparib | 0310-0668 |
| >Company | >Ingredient | >NDC |
OLAPARIB drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch